1. Synthesis and biological evaluation of CHX-DAPYs as HIV-1 non-nucleoside reverse transcriptase inhibitors.
- Author
-
Yan ZH, Wu HQ, Chen WX, Wu Y, Piao HR, He QQ, Chen FE, De Clercq E, and Pannecouque C
- Subjects
- Cell Survival drug effects, Cells, Cultured, HIV-1 drug effects, Humans, Models, Molecular, Molecular Docking Simulation, Molecular Structure, Nitriles, Precursor Cell Lymphoblastic Leukemia-Lymphoma drug therapy, Precursor Cell Lymphoblastic Leukemia-Lymphoma pathology, Precursor Cell Lymphoblastic Leukemia-Lymphoma virology, Pyrimidines chemical synthesis, Pyrimidines chemistry, Structure-Activity Relationship, Tumor Cells, Cultured, Virus Replication drug effects, Anti-HIV Agents chemical synthesis, Anti-HIV Agents pharmacology, Benzamides chemical synthesis, Benzamides pharmacology, Drug Design, HIV Reverse Transcriptase antagonists & inhibitors, Pyrimidines pharmacology, Reverse Transcriptase Inhibitors chemical synthesis, Reverse Transcriptase Inhibitors pharmacology
- Abstract
A series of new diarylpyrimidines (DAPYs) characterized by a halogen atom on the methylene linker between wing I and the central pyrimidine ring was synthesized and evaluated for their anti-HIV activity in MT-4 cell cultures. The two most promising compounds 7f and 7g showed excellent activity against wild-type HIV-1 with low nanomolar EC50 values of 0.005 and 0.009 μM, respectively, which were comparable to or more potent than all the reference drugs zidovudine (AZT), lamivudine (3TC), nevirapine (NEV), efavirenz (EFV), delaviridine (DLV) and etravirine (ETV). In particular, 7g also displayed strong activity against the double mutant strain 103N + 181C with an EC50 value of 8.2 μM. The preliminary structure-activity relationship (SAR) and molecular docking analysis of this new series of CHX-DAPYs were also investigated., (Copyright © 2014 Elsevier Ltd. All rights reserved.)
- Published
- 2014
- Full Text
- View/download PDF